Cargando…

Blunted humoral response after mRNA vaccine in patients with haematological malignancies

Detalles Bibliográficos
Autor principal:	Kamboj, Mini
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Ltd. 2021
Materias:	Comment
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8253544/ https://www.ncbi.nlm.nih.gov/pubmed/34224666 http://dx.doi.org/10.1016/S2352-3026(21)00197-6

Ejemplares similares

Humoral and cellular immune responses to mRNA COVID-19 vaccines in patients with axial spondyloarthritis treated with adalimumab or secukinumab
por: Smetanova, Jitka, et al.
Publicado: (2022)

The antibody response of haematological malignancies to COVID-19 infection and vaccination
por: Seebacher, Nicole A.
Publicado: (2022)

COVID-19 vaccines for patients with haematological conditions
por: Sun, Clare, et al.
Publicado: (2021)

Adult-onset Still's disease after mRNA COVID-19 vaccine
por: Magliulo, Daniel, et al.
Publicado: (2021)

Impact of donor vaccination on recipient response to early SARS-CoV-2 mRNA vaccination after allogeneic HSCT
por: Leclerc, Mathieu, et al.
Publicado: (2022)

COVID-19 mRNA vaccination and myocarditis or pericarditis
por: Husby, Anders, et al.
Publicado: (2022)

Humoral response to mRNA‐based COVID‐19 vaccine in patients with myeloid malignancies
por: Mori, Akio, et al.
Publicado: (2022)

Myocarditis after COVID-19 mRNA vaccination: clinical observations and potential mechanisms
por: Heymans, Stephane, et al.
Publicado: (2021)

Safety of mRNA COVID-19 vaccines during pregnancy
por: Ellington, Sascha, et al.
Publicado: (2022)

Safety and reactogenicity of second booster doses for mRNA vaccines
por: Wilder-Smith, Annelies, et al.
Publicado: (2023)

COVID-19 and haematological malignancy: navigating a narrow strait
por: Rubinstein, Samuel M, et al.
Publicado: (2020)

Impact of methotrexate on first-dose COVID-19 mRNA vaccination
por: Connolly, Caoilfhionn M, et al.
Publicado: (2021)

Recovery from mRNA COVID-19 vaccine-related myocarditis
por: Ammirati, Enrico, et al.
Publicado: (2022)

Anti-SARS-CoV-2 mRNA vaccine in patients with rheumatoid arthritis
por: Rubbert-Roth, Andrea, et al.
Publicado: (2021)

Immunogenicity after second and third mRNA-1273 vaccination doses in patients receiving chemotherapy, immunotherapy, or both for solid tumours
por: Oosting, Sjoukje F, et al.
Publicado: (2022)

Preliminary evidence of blunted humoral response to SARS-CoV-2 mRNA vaccine in multiple sclerosis patients treated with ocrelizumab
por: Gallo, Antonio, et al.
Publicado: (2021)

SARS-CoV-2 mRNA vaccination and subsequent herpes zoster: Possible immune reconstitution by mRNA vaccination
por: Ota, Mitsuhito
Publicado: (2022)

Mixing mRNA, adenoviral, and spike-adjuvant vaccines for protection against COVID-19
por: Richardson, Christopher D
Publicado: (2022)

CS-2034 mRNA vaccine: a new option for COVID-19 infection?
por: Zhang, Ruiqi, et al.
Publicado: (2023)

Antibody durability 6 months after two doses of SARS-CoV-2 mRNA vaccines in patients with rheumatic and musculoskeletal disease
por: Frey, Sarah, et al.
Publicado: (2022)

Third primary SARS-CoV-2 mRNA vaccines enhance antibody responses in most patients with haematological malignancies
por: Cook, Lucy B., et al.
Publicado: (2022)

Acute tolerance of Moderna mRNA-1273 vaccine against COVID-19 in patients with cancer treated with radiotherapy
por: Scoccianti, Silvia, et al.
Publicado: (2021)

Immunogenicity and safety of BNT162b2 mRNA vaccine booster in actively treated patients with cancer
por: Ligumsky, Hagai, et al.
Publicado: (2022)

What a second booster dose of mRNA COVID-19 vaccines tells us
por: Loubet, Paul, et al.
Publicado: (2022)

Impact of anti-PEG antibodies induced by SARS-CoV-2 mRNA vaccines
por: Ju, Yi, et al.
Publicado: (2022)

Is the attenuated humoral response to COVID-19 vaccination in anti-TNF users relevant?
por: Chhibba, Tarun, et al.
Publicado: (2022)

SARS-CoV-2 vaccination in haemodialysis patients: Insides from a prospective study comparing mRNA and viral vector vaccines
por: Füessl, Louise, et al.
Publicado: (2022)

P1570: SARS-COV-2 HUMORAL AND CELLULAR VACCINATION RESPONSE IN PATIENTS WITH LYMPHOID HAEMATOLOGICAL MALIGNANCIES
por: Boerenkamp, L. S., et al.
Publicado: (2022)

COVID-19 mRNA vaccine safety during the first 6 months of roll-out in the USA
por: Krantz, Matthew S, et al.
Publicado: (2022)

Don’t blame the messenger: lessons learned for cancer mRNA vaccines during the COVID-19 pandemic
por: Morris, Van K., et al.
Publicado: (2022)

Effectiveness of bivalent mRNA booster vaccines against COVID-19: methodological and public health considerations
por: Stoliaroff-Pepin, Anna, et al.
Publicado: (2023)

Comment on Zamfir et al. Hematologic Malignancies Diagnosed in the Context of the mRNA COVID-19 Vaccination Campaign: A Report of Two Cases. Medicina 2022, 58, 874
por: Çınar, Olgu Erkin, et al.
Publicado: (2022)

Fourth mRNA COVID-19 vaccination in immunocompromised patients with haematological malignancies (COBRA KAI): a cohort study
por: Hofsink, Quincy, et al.
Publicado: (2023)

Cellular and humoral immunity after the third dose of SARS-CoV-2 vaccine in patients treated with rituximab
por: Felten, Renaud, et al.
Publicado: (2022)

Humoral response to mRNA vaccines against SARS-CoV-2 in patients with humoral immunodeficiency disease
por: Bitzenhofer, Michaela, et al.
Publicado: (2022)

Effectiveness of mRNA booster doses against the omicron variant
por: Zedan, Hadeel T, et al.
Publicado: (2022)

The problem of selection bias in studies of pre-mRNA splicing
por: Dwyer, Zachary W., et al.
Publicado: (2023)

Humoral response following SARS-CoV-2 vaccination: not all immunosuppressants are created equal
por: Connolly, Caoilfhionn M, et al.
Publicado: (2022)

Emerging links between m(6)A and misregulated mRNA methylation in cancer
por: Jaffrey, Samie R., et al.
Publicado: (2017)

Humoral response to mRNA‐based COVID‐19 vaccine in patients with immune thrombocytopenia
por: Mori, Akio, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_cg6l4u2ct666n14ks2iqovoggb